Jensen J.T., Reinecke I., Post T.M. , Lukkari-Lax E. , Hofmann B.M. Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs. Contraception, 2023. [Link to publication].
Reinecke I., Hofmann B., Mesic E., Drenth H.J., Garmann D. An integrated population pharmacokinetic analysis to characterize levonorgestrel pharmacokinetics after different administration routes. J Clin Pharmacol: 1639-1654, 2018. [Link to publication]
Bosch R., Gao W., Vargo R., Baliathan C., Fancourt C., Kothare P.A., Kjellson M.C., Karlsson M. and Post T., Application of a Semi-Mechanistic, Integrated Glucose-Insulin Model to Graded Glucose Infusion Placebo Data to translate Glucose Insulin dynamics between Healthy Humans and Non-Human Primates. PAGE.(2015) [Link to publication]
Berkhout J., Stone J.A., Verhamme K.M., Stricker B.H., Sturkenboom M.C., Danhof M., and Post T.M., Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis, CPT Pharmacometrics Syst Pharmacol., 4(9): 516-526. 2015. [Link to publication]
Reif S., Snelder N., and Blode H., Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study, J Fam Plann Reprod Health Care., 39(2): e1. doi: 10.1136/jfprhc-2012-100397., 2013. [Link to publication]
Strougo A., Elassais-Schaap J., Greef R.d. and Drenth H., Mechanism-based model of effect of co-administration of exogenous testosterone and progestogens on the hypogonadalaxis in men. PAGE. (2007). [Link to publication]